|
|
|
| home > ict > Autumn 2017 |
|
|
 PUBLICATIONS |
International Clinical Trials |
|
|
|
|
|
 |
| |
|
|
Editor’s Comment
Dr Graham Hughes, Editor of ICT, takes a look at some of the key discussion points of this issue, touching on the Internet of Everything, the development of medical devices and the recently instigated EU directives.
|
|
|
|
|
European Focus
Restricting Regulations
Rules and regulations often slowdown clinical trial practices, affecting the processing time between thelaboratory and the consumer. Craig Morgan at goBalto asks whether there is anyopportunity for change in Europe.
|
|
|
|
Mental Health Research
A New Horizon
With mental health often overlooked, Professor Kathryn Abel at NIHR examines new, low-cost methods that could help clinical studies in this particular field.
|
|
|
Managing Cell and Gene Therapies
Perfect Planning
As the worldwide market for regenerative medicines continues to grow, Lisa Vocat at World Courier talks about the logistical challenges now faced when developing new drugs for this therapeutic area.
|
|
|
Trials in Pneumonia
Problematic Patterns
The team at PSI CRO discuss how distinguishing trends followed by serious adverse effects is vital when large amounts of new antibiotics are being tested for community acquired pneumonia.
|
|
|
Unifying Operations
Better Together
Rik Van Mol at Veeva Systems believes the answer to questions surrounding streamlining clinical systems is industry-wide operational continuity.
|
|
|
|
|
Serialisation Beyond Compliance
Keeping Track
Serialisation is an essential factor in maintaining compliance, but Steve Wood at Covectra notes its potential in other areas, such as anti-counterfeiting and delivery to end-users.
|
|
|
|
|
Mobile Services
Closer to Home
The incorporation of mobile units within patient recruitment can improve retention and enrolment rates. Lindsey Copeland and Diane Campbell at CK Aspire discuss the impact this has on clinical trials.
|
|
|
Translation and Local Knowledge
In Other Words
Gary Muddyman at Conversis analyses the complex undertaking of communicating messages to a global audience, highlighting the importance of tailoring your content and ensuring quality of data.
|
|
|
|
|
Q&A: Adapting to New Regulations
Hindering Hazards
Patrick Hughes at CluePoints explains the impact of new regulatory updates in trial quality maintenance, specifically covering ICH E6 R2, and how pharma companies can handle this shift.
|
|
|
|
|
IoE in Clinical Trails
Superior Strategy
CRF Health’s Richard Strobridge reflects on how the Internet of Everything could positively impact healthcare in terms of improved patient experience and focus within clinical trials.
|
|
|
Wearable Technology
Fastening Pharmaceuticals
Jeremy Wheeler at Quanticate reviews the noticeable benefits that incorporating wearable medical devices may have or pharma companies trying to bring new medicines to the market.
|
|
|
New Developments in Patient Outcomes
Technological Takeover
IBM Watson Health’s Jeff Beeler and Alysa Lesemann consider how patient-reported outcomes, alongside new technological reporting methods, can provide guidance
when developing new drugs.
|
|
|
Compliant Packaging
Handle with Care
The shipping of biological substances across borders needs to be rigorously regulated, so Sue Fletcher at Alpha Laboratories Ltd discusses the importance of complying with UN3373.
|
|
|
End Point
A Costly Cause
Looking to the future of clinical trials, ICT editor Dr Graham Hughes emphasises the worrisome impact of the expensive development of precision medicines.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Source BioScience invest in digital pathology platform to enhance the outsourced histopathology service solution provided to the NHS and private healthcare
As a leading provider of outsourced histopathology services
to the NHS and private healthcare centres in the UK Source BioScience has,
after a detailed review of all other available alternatives in the digital marketplace,
unveiled investment in a digital pathology platform from their preferred
partner, Philips.
More info >> |
|
 |
White Papers |
 |
|
Orthogonal Approaches for the Analysis of Protein Sequence
Ludger Ltd
One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >> |
|
 |
Industry Events |
 |
PPMA SHOW 2018
25-27 September 2018, NEC, Birmingham, UK
The UK’s leading production line event is celebrating
its 30th Anniversary. Taking place at the NEC, Birmingham from 25-27
September 2018, the exhibition showcases the latest processing and packaging
machinery. Attended by thousands of manufacturers of food, pharmaceuticals and
FMCG as well as contract packers and more.
More info >> |
|
|
